ChemoCentryx to Present at Two Upcoming Investor Conferences
February 25 2021 - 8:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at two upcoming investor conferences:
Raymond James 42nd Annual Institutional
Investors ConferenceWednesday, March 3 at 2:10 p.m.
Eastern Time
H.C. Wainwright Global Life Sciences
ConferenceOn-demand presentation available beginning
Monday, March 9 at 7:00 a.m. Eastern Time
Webcasts of the presentations can be accessed through the
Investors section of the Company's website at www.ChemoCentryx.com.
A replay of each presentation will be available on the Company's
website for two weeks following the respective presentation
dates.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications for inflammatory and autoimmune diseases and cancer.
ChemoCentryx targets the chemokine and chemoattractant systems to
discover, develop and commercialize orally administered therapies.
ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully
completed a pivotal Phase III trial in ANCA-associated vasculitis
and a New Drug Application is under review by the U.S. Food and
Drug Administration. Avacopan is also in late-stage clinical
development for the treatment of severe Hidradenitis Suppurativa
and C3 glomerulopathy (C3G).
ChemoCentryx also has early-stage drug candidates that target
chemoattractant receptors in other inflammatory and autoimmune
diseases and in cancer.
Contacts:
Susan M.
Kanaya Executive
Vice President,
Chief
Financial and Administrative Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Lee Roth, Burns McClellan212.213.0006
lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Sep 2023 to Sep 2024